Metrika

  • citati u SCIndeksu: 0
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[]
  • posete u poslednjih 30 dana:1
  • preuzimanja u poslednjih 30 dana:1

Sadržaj

članak: 8 od 53  
Back povratak na rezultate
2016, vol. 73, br. 11, str. 1022-1029
Korelacija lokalne i sistemske ekspresije survivina sa patohistološkim parametrima melanoma kože
aVojnomedicinska akademija, Institut za patologiju i sudsku medicinu, Beograd
bVojnomedicinska akademija, Institut za patologiju i sudsku medicinu, Beograd + Univerzitet odbrane, Medicinski fakultet Vojnomedicinske akademije, Beograd
cUniverzitet odbrane, Medicinski fakultet Vojnomedicinske akademije, Beograd + Vojnomedicinska akademija, Klinika za plastičnu hirurgiju i opekotine, Beograd
dUniverzitet odbrane, Medicinski fakultet Vojnomedicinske akademije, Beograd + Vojnomedicinska akademija, Institut za medicinska istraživanja, Beograd
eDorset County Hospital Foundation Trust, Dorchester, United Kingdom
fUniverzitet u Beogradu, Farmaceutski fakultet, Institut za toksikološku hemiju
gDepartment of Physiology and Pharmacology, Sapienza University, Rome, Italy
hUniverzitet odbrane, Medicinski fakultet Vojnomedicinske akademije, Beograd + Vojnomedicinska akademija, Institut za naučne informacije, Beograd

e-adresaalhemastro@gmail.com
Sažetak
Uvod/Cilj. Survivin je multifunkcionalni protein bogato ispoljen u tumorima različite vrste, uključujući i melanom. Retki su radovi koji opisuju odnos ispoljavanja survivina u melanomskim ćelijama sa njegovom serumskom koncentracijom kao i sa histopatološkim karakteristikama melanoma. Cilj rada bio je da se ispita udruženost lokalne ekspresije survivina u tumoru (primarni tumor i metastatske promene) i serumske koncentracije sa kliničkim i histopatološkim parametrima kod bolesnika sa melanomom. Metode. Nivo ekspresije survivina određivan je imunocitohistohemijski utumorskom tkivu i ELISA testom u serumu 84 bolesnika sa melanomom, dijagnostikovanih u periodu od 2009. do 2013. na Institutu za patologiju i sudsku medicínu i Institutu za medicinska istraživanja na Vojnomedicinskoj akademiji, Beograd, Srbija. Rezultati. Intezitet ekspresije survivina bio je značajno veći kod bolesnika čiji su tumori bili ulcerisani, sa visokim mitotskim indeksom, visokim Clark i Breslow indeksom, sa prisutnom vaskularnom i limfnom invazijom, kao i kod onih sa metastatskom bolesti. Ispoljavanje survivina i broj survivin pozitivnih ćelija u metastatskim lezijama bio je značajno udružen sa trajanjem intervala bez bolesti (disease free interval - DFI). Bolesnici sa visokim skorom ekspresije imali su skoro dvostruko kraći DFI u odnosu na one sa sla­bom lokalnom ekspresijom survivina i malim brojem survivin pozitivnih ćelija (9 ± 7 vs 19 ± 13 meseci). Stepen prisustva tumor infltrišućih limfocita u tumorskom tkivu bio je značajno udružen sa koncetracijom survivina u serumu, sa najnižim prosečnim vrednostima detektovanim u uzorcima bolesnika sa najvećim stepenom infiltracije. Serumske koncentracije survivina bile su najveće u uzorcima bolesnika sa melanomom IA kliničkog stadijuma American Joint Commission on Cancer (AJCC), pT1a histološkog stadijuma, bolesnika čiji su tumori bili u horizontalnoj fazi rasta, bez znakova širenja limfohematogenim putem, sa najvećim brojem mitoza i koji su imali najmanji Clark indeks. Zaključak. Ekspresija survivina u tumorskom tkivu i njegova serumska koncentracija značajno korelišu sa kliničkim i histopatološkim parametrima melanoma. Serumski nivo može biti važan kao inicijalni indikator kod onih bolesnika koji bi mogli imati agresivan lokalni tumorski rast i širenje. Određivanje survivina u tumorskom tkivu, kako u primarnom tumoru tako i u metastazama, od velikog je značaja u utvrđivanju trajanja DFI.
Reference
Adamkov, M., Lauko, L., Balentova, S., Pec, J., Pec, M., Rajcani, J. (2009) Expression pattern of anti-apoptotic protein survivin in dysplastic nevi. Neoplasma, 56(2): 130-5
Adamkov, M., Lauko, L., Rajčáni, J., Bálentová, S., Rybárová, S., Mištuna, D., Statelová, D. (2009) Expression of antiapoptotic protein survivin in malignant melanoma. Biologia, 64(4)
Altień, D.C. (2003) Survivin in apoptosis control and cell cycle regulation in cancer. Prog Cell Cycle Res, 5: 447-52
Altieri, D.C. (2003) Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene, 22(53): 8581-9
Andersen, M.H., Svane, I.M., Becker, J.C., Straten, P.T. (2007) The universal character of the tumor-associated antigen survivin. Clinical cancer research, 13(20): 5991-4
Cohen, C., Lohmann, C.M., Cotsonis, G., Lawson, D., Santoianni, R. (2003) Survivin expression in ovarian carcinoma: correlation with apoptotic markers and prognosis. Modern pathology, 16(6): 574-83
Colnaghi, R., Connell, C.M., Barrett, R.M.A., Wheatley, S.P. (2006) Separating the anti-apoptotic and mitotic roles of survivin. Journal of biological chemistry, 281(44): 33450-6
Dadras, S.S. (2011) Molecular diagnostics in melanoma: current status and perspectives. Archives of pathology & laboratory medicine, 135(7): 860-9
Ding, Y., Prieto, V.G., Zhang, P.S., Rosenthal, S., Smith, K.J., Skelton, H.G., Diwan, A. (2006) Nuclear expression of the antiapoptotic protein survivin in malignant melanoma. Cancer, 106(5): 1123-9
Ellebaek, E., Iversen, T., Junker, N., Donia, M., Engell-Noerregaard, L., Met, Ö., Hölmich, L., Andersen, R., Hadrup, S., Andersen, M., Straten, P.thor, Svane, I. (2012) Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients. Journal of Translational Medicine, 10(1): 169
Fields, A.C., Cotsonis, G., Sexton, D., Santoianni, R., Cohen, C. (2004) Survivin expression in hepatocellular carcinoma: correlation with proliferation, prognostic parameters, and outcome. Modern Pathology, 17(11): 1378-1385
Goksel, G., Taneli, F., Uslu, R., Ulman, C., Dinc, G., Coskun, T., Kandiloglu, A. (2007) Serum Her-2/neu and Survivin Levels and Their Relationship to Histological Parameters in Early-stage Breast Cancer. Journal of International Medical Research, 35(2): 165-172
Grossman, D., McNiff, J.M., Li, F., Altieri, D.C. (1999) Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. Journal of investigative dermatology, 113(6): 1076-81
Hadrup, S.R., Braendstrup, O., Jacobsen, G.K., Mortensen, S., Pedersen, L.Ø., Seremet, T., Andersen, M.H., Becker, J.C., Straten, P.T. (2006) Tumor infiltrating lymphocytes in seminoma lesions comprise clonally expanded cytotoxic T cells. International journal of cancer, 119(4): 831-8
Hadrup, S.R., Gehl, J., Sørensen, R.B., Geertsen, P.F., Straten, P.T., Andersen, M.H. (2006) Persistence of survivin specific T cells for seven years in a melanoma patient during complete remission. Cancer biology & therapy, 5(5): 480-2
Junker, N., Straten, P.thor, Andersen, M.H., Svane, I.M. (2011) Characterization of Ex Vivo Expanded Tumor Infiltrating Lymphocytes from Patients with Malignant Melanoma for Clinical Application. Journal of Skin Cancer, 2011: 1-6
Junker, N., Munir, S., Kvistborg, P., Straten, P.thor, Svane, I.M., Andersen, M.H. (2012) A Promiscuous Survivin-Derived T-Cell Epitope Restricted to the HLA-A3 Super-Type Alleles. Journal of Investigative Dermatology, 132(8): 2115-2118
Khan, S., Jutzy, J.M.S., Aspe, J.R., McGregor, D.W., Neidigh, J.W., Wall, N.R. (2011) Survivin is released from cancer cells via exosomes. Apoptosis, 16(1): 1-12
Khan, S., Bennit, H.F., Turay, D., Perez, M., Mirshahidi, S., Yuan, Y., Wall, N.R. (2014) Early diagnostic value of survivin and its alternative splice variants in breast cancer. BMC Cancer, 14(1)
McKenzie, J.A., Grossman, D. (2012) Role of the apoptotic and mitotic regulator survivin in melanoma. Anticancer research, 32(2): 397-404
McKenzie, J.A., Liu, T., Goodson, A.G., Grossman, D. (2010) Survivin enhances motility of melanoma cells by supporting Akt activation and {alpha}5 integrin upregulation. Cancer research, 70(20): 7927-37
McKenzie, J.A., Liu, T., Jung, J.Y., Jones, B.B., Ekiz, H.A., Welm, A.L., Grossman, D. (2013) Survivin promotion of melanoma metastasis requires upregulation of α5 integrin. Carcinogenesis, 34(9): 2137-44
Nassar, A., Lawson, D., Cotsonis, G., Cohen, C. (2008) Survivin and Caspase-3 Expression in Breast Cancer: Correlation With Prognostic Parameters, Proliferation, Angiogenesis, and Outcome. Applied Immunohistochemistry & Molecular Morphology, 16(2): 113-120
Piras, F., Murtas, D., Minerba, L., Ugalde, J., Floris, C., Maxia, C., Colombari, R., Perra, M.T., Sirigu, P. (2007) Nuclear survivin is associated with disease recurrence and poor survival in patients with cutaneous malignant melanoma. Histopathology, 50(7): 835-42
Qi, Y., Li, X., Li, H., Zheng, Y. (2013) The Research of Nanocrystallized Realgar for the Treatment of Skin Cancer. Journal of Cancer Therapy, 04(06): 43-47
Raimondo, S., Saieva, L., Corrado, C., Fontana, S., Flugy, A., Rizzo, A., de Leo, G., Alessandro, R. (2015) Chronic myeloid leukemia-derived exosomes promote tumor growth through an autocrine mechanism. Cell Communication and Signaling, 13(1): 8
Reed, J.C. (2001) The Survivin saga goes in vivo. Journal of clinical investigation, 108(7): 965-9
Reker, S., Becker, J.C., Svane, I.M., Ralfkiaer, E., Straten, P., Andersen, M.H. (2004) HLA-B35-restricted immune responses against survivin in cancer patients. International journal of cancer, 108(6): 937-41
Schramm, S., Mann, G.J. (2011) Melanoma prognosis: a REMARK-based systematic review and bioinformatic analysis of immunohistochemical and gene microarray studies. Molecular cancer therapeutics, 10(8): 1520-8
Srinivasula, S.M., Ashwell, J.D. (2008) IAPs: what's in a name?. Molecular cell, 30(2): 123-35
Takai, N., Miyazaki, T., Nishida, M., Nasu, K., Miyakawa, I. (2002) Survivin expression correlates with clinical stage, histological grade, invasive behavior and survival rate in endometrial carcinoma. Cancer letters, 184(1): 105-16
Takeuchi, H., Morton, D.L., Elashoff, D., Hoon, D.S.B. (2005) Survivin expression by metastatic melanoma predicts poor disease outcome in patients receiving adjuvant polyvalent vaccine. International journal of cancer, 117(6): 1032-8
Tanaka, K., Iwamoto, S., Gon, G., Nohara, T., Iwamoto, M., Tanigawa, N. (2000) Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clinical cancer research : an official journal of the American Association for Cancer Research, 6(1): 127-34
Tas, F., Duranyildiz, D., Argon, A., Oguz, H., Camlica, H., Yasasever, V., Topuz, E. (2004) Serum bcl-2 and survivin levels in melanoma. Melanoma research, 14(6): 543-6
Thomas, J., Liu, T., Cotter, M.A., Florell, S.R., Robinette, K., Hanks, A.N., Grossman, D. (2007) Melanocyte expression of survivin promotes development and metastasis of UV-induced melanoma in HGF-transgenic mice. Cancer research, 67(11): 5172-8
Tsai, W., Chu, C., Yu, C., Sheu, L., Chen, A., Chiang, H., Jin, J. (2008) Matriptase and survivin expression associated with tumor progression and malignant potential in breast cancer of Chinese women: tissue microarray analysis of immunostaining scores with clinicopathological parameters. Disease markers, 24(2): 89-99
Vetter, C.S., Müller-Blech, K., Schrama, D., Bröcker, E.B., Becker, J.C. (2005) Cytoplasmic and nuclear expression of survivin in melanocytic skin lesions. Archives of dermatological research, 297(1): 26-30
 

O članku

jezik rada: engleski
vrsta rada: izvorni naučni članak
DOI: 10.2298/VSP150519119J
objavljen u SCIndeksu: 05.11.2016.
metod recenzije: dvostruko anoniman
Creative Commons License 4.0